Exciting New Therapies for Advanced Melanoma – A Patient Power Video

http://youtu.be/RijCE3bkSMw New clinical trials data presented at ASCO 2011 revealed a striking response to drugs ipilimumab (recently-approved), and vemurafenib, a new drug for patients with the most common subtype of advanced melanoma (B-RAF V600E Mutation). Dr. Kim Margolin, a Melanoma specialist at the Fred Hutchinson Cancer Research Institute in Seattle helped us understand why this new drug is making news and why patients have reason to be hopeful.